Clinical trials involving JAK-inhibitors in COVID-19 (7/20/2020)
| JAK-inhibitor | Phase 2 | Phase 3 | Phase 4 |
|---|---|---|---|
| Baricitinib (12 total) | NCT04373044 | NCT04340232 | NCT04390464 |
| NCT04393051 | NCT04358614 | ||
| NCT04346147 | NCT04320277 | ||
| NCT04321993 | NCT04421027 | ||
| NCT04399798 | NCT04401579 | ||
| NCT04345289 | |||
| Ruxolitinib (14 total) | NCT04334044 | NCT04348071 | |
| NCT04414098 | NCT04477993 | ||
| NCT04354714 | NCT04377620 | ||
| NCT04366232 | NCT04362137 | ||
| NCT04338958 | NCT04424056 | ||
| NCT04374149 | |||
| NCT04359290 | |||
| NCT04403243 | |||
| NCT04348695 | |||
| Tofacitinib (5 total) | NCT04412252 | ||
| NCT04415151 | |||
| NCT04469114 | |||
| NCT04390061 | |||
| NCT04332042 | |||
Source: www.clinicaltrials.gov